While Symmetry Medical
What analysts say:
- Buy, sell, or hold?: Analysts strongly back Symmetry Medical, with four of five rating it a buy and the remainder rating it a hold. Analysts like Symmetry Medical better than competitor RTI Biologics overall. Analysts still rate the stock a moderate buy, but they are a bit more wary about it compared to three months ago.
- Revenue forecasts: On average, analysts predict $80.8 million in revenue this quarter. That would represent a decline of 15.8% from the year-ago quarter.
- Wall Street earnings expectations: The average analyst estimate is earnings of $0.04 per share. Estimates range from $0.03 to $0.07.
What our community says:
CAPS All Stars are strongly backing the stock, with 87% assigning it an "outperform" rating. Most of the community backs the All Stars, with 89.5% giving it a rating of "outperform." Despite the majority sentiment in favor of Symmetry Medical, the stock has a middling CAPS rating of three out of five stars.
A year-over-year revenue decrease last quarter snaps a streak of three consecutive quarters of revenue increases. The company's gross margin shrank by 2.9 percentage points in the last quarter. Revenue fell 8.2%, while cost of sales fell 4.8% to $68.3 million from a year earlier.
We can help you keep tabs on your companies with My Watchlist, our free, personalized service. Add Symmetry Medical now.
Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.Earnings estimates provided by Zacks.